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Abstract: The aim of this study was to evaluate the serological diagnostic potential of the Brucella recombinant outer membrane
(rOMP25, rOMP31) and periplasmic proteins (rBP26, rSOD) in a comparative way using an indirect enzyme-linked immunosorbent
assay (i-ELISA). Rabbit and/or mouse antibodies to Brucella whole cell and/or soluble protein preparations recognized all recombinant
proteins used, which confirms the expression of target antigens in E. coli in active form. The recombinant proteins showed different
antigenicity to antibodies of cattle kept on a brucellosis-affected (endemic) farm and/or a new focus of infection. Thus, the presence of
anti-Brucella antibodies was confirmed by i-ELISA/rSOD in 79% of cows from endemic conditions with positive results by conventional
serological tests (RBPT and/or CFT). However, antibodies specific to this protein were detected in only 14% of seropositive animals kept
in the hotbed of a new brucellosis infection. Moreover, rSOD-specific antibodies were not detected in the sera of vaccinated cattle from
a brucellosis-free farm, whereas antibodies to other recombinant proteins were found in 2%–8% of animals. Using recombinant proteins
in immunoassays significantly reduced the number of cows positive for brucellosis. Furthermore, there was not a single protein among
the rOMPs that would show the total positive results of all proteins used. Thus, the development of reliable ELISA tests for the diagnosis
of brucellosis requires further comprehensive study of the recombinant proteins in order to design a multiprotein antigen that consists
of a combination of several proteins with diagnostic potential.
Key words: Brucellosis, cattle, diagnosis, recombinant proteins, enzyme-linked immunosorbent assay

1. Introduction
Brucellosis is one of the most common zoonotic infections
that negatively affects livestock productivity and leads
to lifelong disability [1]. More than half a million new
cases of human brucellosis are recorded worldwide every
year, although this figure is considered to be largely
underreported. Kazakhstan, as well as six other former
Soviet republics (Kyrgyzstan, Tajikistan, Azerbaijan,
Turkmenistan, Armenia, and Uzbekistan), is among the 25
countries with the highest incidence of the disease [2]. An
early diagnosis of Brucella-infected animals is a key element
in eradication programs. For this purpose, conventional
serological tests, such as the serum agglutination test
(SAT), Rose Bengal plate test (RBPT), complement
fixation test (CFT), and enzyme-linked immunosorbent
assay (ELISA), have been widely used [3]. In these tests
smooth lipopolysaccharides (S-LPS) of Brucella spp., the
most superficial layer of the cell wall, have been mainly
used to identify pathogen-specific antibodies. Therefore, it
is very difficult to differentiate animals immunized using
live attenuated vaccines from naturally Brucella-infected

animals [4]. Moreover, traditional tests based on the use
of Brucella whole cell S-LPS as an antigen do not always
give reliable results because of cross-reactivity with other
gram-negative bacteria, such as Yersinia enterocolitica
O:9 [5], Escherichia coli O157:H7 [6], Salmonella
spp., or Pseudomonas maltophilia [7]. In this regard,
Brucella immunogenic proteins have been the focus of
attention of researchers engaged in the development of
diagnostic kits for brucellosis and vaccine design [8].
At least 67 proteins, including 4 major outer membrane
proteins (OMPs), have been described as part of the
outer membrane-peptidoglycan complex from B. abortus
[9]. OMPs were classified according to their apparent
molecular weight as 36–38 kDa OMPs or group 2 porin
proteins and 31–34 and 25–27 kDa OMPs, which belong to
the group 3 proteins [10]. Advances in genetic engineering
have made it possible to study the use of recombinant
OMPs (rOMPs) as antigens to avoid biological hazards
associated with the use of viable Brucella strains. Besides,
“a test based on recombinant proteins would allow better
standardization of the assay, compared with more complex
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whole-cell antigen preparations currently in use, and
hence overcome the limitations associated with the use
of LPS-based antigens” [11]. Among the known rOMPs,
the most studied ones are rOMP25 [12] and rOMP31 [13].
Another group of recombinant proteins, which is of great
interest from a diagnostic point of view, are periplasmic
proteins: rBP26 or rOMP28 [14] and Cu-Zn superoxide
dismutases (rSOD) [15]. However, the comparative
diagnostic value of these two groups of Brucella proteins is
still scarcely explored. The aim of our study was to evaluate
the serological diagnostic potential of Brucella rOMPs and
periplasmic proteins in a comparative way using indirect
ELISA (i-ELISA).
2. Materials and methods
2.1. Experimental animals
Fifteen white outbred male mice (8–10 weeks, 20–25
g body weight) and a Soviet Chinchilla male rabbit (6
months, 3300 g body weight) were kept under good
hygienic conditions in the vivarium of S. Seifullin Kazakh
Agrotechnical University (KATU), Astana, and their use
and care were approved by the Animal Ethics Committee,
Faculty of Veterinary and Livestock Technology, KATU.
The animals were provided with food and water ad libitum.
A 12-h lighting cycle was maintained in the animal
housing. Temperature and humidity were monitored daily.
All activities involving animals were carried out according
to the Guidance for Accommodation and Care of Animals:
Species-Specific Provisions for Laboratory Rodents and
Rabbits (Interstate Standard, GOST 33216-2014).
2.2. Microbial cultures
Whole cells of B. abortus 19, inactivated with phosphatebuffered saline (PBS) containing 0.5% phenol at 37 °C for
48 h, were kindly provided by the Research and Production
Enterprise “Antigen”, Almaty, Kazakhstan.
Escherichia coli BL21 strains, producing Brucella
recombinant proteins, were obtained as described in our
previous studies: B. abortus rOMP25 and B. melitensis
rOMP31 [16], rBP26 [14], and rSOD [17].
2.3. Preparation of Brucella proteins
Extraction of soluble protein preparations (CSPs)
from whole cells of B. abortus 19 was based on the elution
of the membrane proteins with 0.1 M sodium citrate
solution (Sigma-Aldrich, St. Louis, MO, USA) containing
1 M sodium chloride (Fisher Chemical, Loughborough,
UK) and 0.1% Triton X-100 (Sigma-Aldrich) [18].
E. coli strains, producing Brucella recombinant
proteins, were grown in Luria-Bertani liquid medium
containing 1% baktotripton, 0.5% yeast extract (all from
Thermo Fisher Scientific, Waltham, MA, USA), and 1%
NaCl supplemented with ampicillin (Sintez, Kurgan,
Russia) at a concentration of 100 µg/mL. In the middle
of the logarithmic growth phase of the bacterial mass

(absorbance at λ = 600 nm, OD600 = 0.6), isopropyl β-D1-thiogalactopyranoside (Sigma-Aldrich) was added to a
final concentration of 1 mM to induce expression of the
recombinant proteins. The culture was incubated at room
temperature for 16 h with shaking and then bacterial cells
were harvested by centrifugation at 5000 × g at 4 °C for
10 min. After that, cells were resuspended in a lysis buffer
(20 mM Tris, pH 7.5; 1 mM EDTA; 100 mM NaCl) in
the amount of 10 mL per 1 g wet weight cells, followed
by the addition of 1 µL of phenylmethanesulfonyl fluoride
(Thermo Fisher Scientific) with a final concentration of 0.2
mM. The bacterial cell suspension was then sonicated using
the ultrasonic homogenizer OMNI-Ruptor 4000 (OMNI
International, Kennesaw, GA, USA) in an ice-water bath.
The recombinant proteins were purified by metal affinity
chromatography using commercial HisTrap columns (GE
Healthcare Life Sciences, Cardiff, UK) according to the
manufacturer’s instructions.
2.4. Immunization of mice with protein antigens
Five groups of 3 mice each were used in this study. The
mice were immunized each with 25 µg of the respective
proteins as follows: the first group with rOMP25, second
group with rOMP31, third group with rВР26, fourth group
with rSOD, and fifth group with B. abortus CSP. Mice were
immunized according to the following scheme: on day 0
the appropriate antigen emulsified in Freund’s incomplete
adjuvant (Sigma-Aldrich) was injected subcutaneously
(s.c.) in an amount of 100 µL. Subsequent injections of
antigen in 200 µL of PBS, pH 7.2–7.4 (Amresco, Solon,
OH, USA) were performed intraperitoneally on days 7, 14,
21, and 28. Preparation of antisera pools was performed
on day 42. Before each immunization blood was taken
from the tail vein into microfuge tubes (Isolab, Wertheim,
Germany) for the determination of antibody titer by
i-ELISA. The control negative sera were sampled on day 0
before the first immunization.
2.5. Determination of antibody titer against Brucella
protein antigens by i-ELISA
The polystyrene plate wells (Thermo Fisher Scientific) were
separately coated with Brucella protein preparations (4 °C
for 18 h) used for immunization of mice at a concentration
of 5.0 µg/mL in bicarbonate buffer, pH 9.6. The contents
of the wells were then removed and the plate was washed
several times with 0.05% Tween-20 (Sigma-Aldrich) in
PBS (PBS-T). The unbound sites of the wells were blocked
with 1% bovine serum albumin (Sigma-Aldrich), and
dilutions of homologous and heterologous antisera as well
as negative control sera in PBS-T were prepared in 8 wells,
starting at 1:100, and incubated at 37 °C for 1 h. After a
washing procedure, horseradish peroxidase (HRP)-labeled
antimouse IgG (Sigma-Aldrich) diluted with PBS-T was
added to the wells. The plate was incubated at 37 °C for
1 h, and the substrate orthophenylenediamine (Sigma-
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Aldrich) was applied. The plate was kept in a dark place
at room temperature. After 3–5 min, an equal amount of
2 M sulfuric acid was added to the wells. The absorbance
was measured at 492 nm using a plate reader (Bio-Rad
680, Redmond, WA, USA). For the titer of antibodies the
dilution of the antiserum was taken, the optical density
(OD) of which was two or more times higher than the OD
of the negative control blood serum at a dilution of 1:100.
2.6. Production of rabbit antiserum against B. abortus 19
whole cells
A rabbit was s.c. immunized with killed B. abortus 19
as previously described [19]. Blood samples were taken
from the ear’s marginal vein under sedation on day 0 as
a negative control, and then every 2 weeks to evaluate
antibody response. The hyperimmune serum was collected
on day 56 and stored at –20 °C until used.
2.7. Serum samples
Sera of 43 cows from a brucellosis-affected (endemic)
farm and of 77 unvaccinated cows from a brucellosis-free
farm, where an outbreak (a new focus) of infection had
been registered during the scheduled serological testing of
animals, were kindly provided by the National Reference
Center for Veterinary Medicine, Kazakh Ministry of
Agriculture, and the Zhetikara Veterinary Laboratory,
Kostanay oblast, respectively. Animals of both groups had
reacted positively to brucellosis by conventional serological
tests (RBPT and/or CFT). Additionally, 48 serum samples
were collected from cows kept on a brucellosis-free farm
(Bukhar Zhyrau rayon, Karaganda oblast), where the B.
abortus 19 vaccine (Schelkovsk Biokombinat, Russia) had
been used for immunization. It is given to female calves
5–6 months old as a single subcutaneous dose of 8 × 1010
organisms. Revaccination of animals is carried out in
11–12 months with the same vaccine comprising 8 × 109
CFU per 0.05 mL by administration to the conjunctiva.
For calculation of a cutoff value of i-ELISA, serum
samples of 20 unvaccinated heifers from the “Rodina”
farm, Tselinograd rayon, Akmola oblast, which has been
brucellosis-free for long periods of time, were obtained.
2.8. Serological examinations of rabbit and cattle sera by
i-ELSA for anti-Brucella antibody
Briefly, the wells of a polystyrene plate (Thermo Fisher
Scientific) were separately coated with the following
Brucella antigens: rOMP25, rOMP31, rBP26, rSOD,
and/or B. abortus CSP. After washing the wells and
blocking active sites of the solid phase, dilutions of cattle
blood serum sample (1:100 and 1:200) and/or rabbit
hyperimmune serum against B. abortus 19 whole cells
(1:100 to 1:12,800) were prepared in the wells. Then,
after 1 h of incubation, antibovine (Sigma-Aldrich) and/
or antirabbit IgG antibodies (Jackson ImmunoResearch,
West Grove, PA, USA) labeled with HRP were added to
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the wells. A cutoff value to distinguish between positive
and negative results of i-ELISA was calculated using the
mean OD of B. abortus-negative sera [20]. For the titer of
rabbit antibodies the dilution of the hyperimmune serum
was taken, whose OD was two or more times higher than
the OD of the negative control serum at a dilution of 1:100.
2.9. Serological examinations of cows from brucellosisfree farm by RBPT
The RBPT (“Antigen”, Almaty, Kazakhstan) was carried out
according to the manufacturer’s instructions.
2.10. Statistical analyses
Statistical analysis of i-ELISA readings was performed
using MS Excel 2007 for Windows 7. The results were
considered significant at a probability level of less than
0.05.
3. Results
The immunogenicity results of Brucella protein
preparations by i-ELISA are shown in the Figure.
The Brucella protein preparations used had a different
immunogenicity. For example, a study of mice blood
samples on day 7 showed the absence of specific antibodies
in animals immunized with rSOD and rBP26. By this time,
the immune response in the form of antibody formation
began to develop in mice immunized with B. abortus CSP,
rOMP25, and rOMP31. Antibodies to rSOD were not
detected even up to day 14, whereas antibody titers of the
analogues injected with rOMP25 and rOMP31 ranged
from 1:200 to 1:800. Attention is drawn to a significant
increase in antibody titer in animals stimulated with rBP26
at 1:6400 to 1:12,800 by that time. Further injections (third
and fourth) of rBP26 into mice did not cause an increase
in the concentration of serum antibodies. After the third
immunization, antibody formation against rOMP25 and
rOMP31 (1:3200 to 1:6400) as well as B. abortus CSP
(1:6400 to 1:12,800) reached its peak (day 21). However,
anti-rSOD antibodies rose to this level only on day 28.
By the end of immunization (on day 42) the titers of
hyperimmune sera against homologous proteins reached
1:12,800 (data not shown).
The results of studying the cross-reactivity of antisera
against heterologous proteins are shown in Table 1.
As can be seen in Table 1, antibodies to Brucella
CSP in a decreasing degree bound to rOMP25 (1:3200),
rOMP31 (1:800), and rBP26 (1:400); however, they did not
recognize rSOD. Antiserum to the last antigen was negative
for all protein preparations used. As might be expected,
rSOD did not react with any antiserum. Cross-reactions of
varying intensity were noted between rOMP25, rOMP31,
and rBP26.
The hyperimmune serum obtained at the end of the
immunization (on day 56) from a rabbit by immunization
with killed B. abortus 19 whole cells had activity against
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Figure. Immunogenicity of Brucella protein antigens in mice. 1, 2, 3 - mice numbers.
Table 1. Cross-reactivity of hyperimmune mice sera to Brucella proteins by i-ELISA.
Antisera titers against Brucella proteins
Types of Brucella proteins

CSP

rOMP31

rSOD

rВP26

rOMP25

CSP

1:12,800

1:400

NR*

NR

1:200

rOMP31

1:800

1:12,800

NR

1:1600

1:400

rSOD

NR

NR

1:12,800

NR

NR

rВP26

1:400

1:400

NR

1:12,800

1:200

rOMP25

1:3200

1:1600

NR

1:400

1:12,800

* NR: Negative result.

Brucella CSP, showing a titer of 1:51,200, and it was used
to determine the antigenicity of Brucella recombinant
proteins by i-ELISA. The results of the immunoassay
showed that hyperimmune serum antibodies bound to
recombinant proteins with a high affinity as detect
ed
by dilutions to 1: 3200 (rOMP31, rBP26) and 1:12,800
(rOMP25, rSOD), which in turn indicated that these
antigens were expressed in E. coli BL21 in active form.
Furthermore, the antigenicity of protein preparations
was studied using blood sera samples of cows from farms
with different epizootic situations regarding brucellosis. To
determine the cutoff value for the enzyme immunoassay,
20 B. abortus-negative heifers’ blood sera were used. The

average OD492 values of brucellosis-negative sera were
0.101 ± 0.010, 0.126 ± 0.012, 0.109 ± 0.008, 0.148 ± 0.013,
and 0.069 ± 0.009 at 1:200-fold dilution for i-ELISA based
on B. abortus CSP, rOMP25, rOMP31, rBP26, and/or
rSОD, and the cutoff values were determined at 0.202,
0.252, 0.218, 0.296, and 0.138, which were double the
average OD492 of negative sera, respectively .
Below are the results of i-ELISA testing of 43 cows kept
on a brucellosis-affected farm (Table 2).
From Table 2 it follows that the use of B. abortus CSP
and rSOD as antigens gave a relatively high sensitivity to
the immunoassay and allowed detection of antibodies
in the largest number of animals studied (86% and 79%,
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respectively), whereas the other three recombinant
proteins detected anti-Brucella antibodies in rather low
numbers of cattle.
There was a high correlation between i-ELISA/
rOMP25 and i-ELISA/rOMP31 (r = 0.72). An appreciable
positive correlation was noted between the results of the
immunoassay based on rOMP25 and rBP26 (r = 0.52),
rOMP31 and rBP26 (r = 0.56), and B. abortus CSP and
rSOD (r = 0.57).
Table 3 shows the results of studying antigenicity of
Brucella proteins using blood serum samples of 77 cows
from a new focus of infection.
B. abortus CSP showed maximum antigenicity by
detecting antibodies in 95% of the cows kept in the hotbed
of new brucellosis infection. It should be noted that the
periplasmic proteins pBP26 and rSOD turned out to be less

antigenic than the OMPs, detecting the presence of specific
antibodies in 30% and 14% of the cattle, respectively.
Among the cows kept on the brucellosis-free farm
subjected to i-ELISA, 11 and 37 of 48 animals had been
vaccinated with B. abortus 19 vaccine 6 months and 11
months before the serological examinations, respectively.
All but one animal (90%) vaccinated 6 months ago showed
a positive result by RBPT, while only 10 animals (27%)
vaccinated 11 months ago were seropositive by this test.
Table 4 presents the results of serological testing of
cows from the brucellosis-free farm by i-ELISA: B. abortus
CSP antibodies were detected by i-ELISA in 23% of the
cattle, whereas, as mentioned above, among the vaccinated
livestock positive RBPT results were obtained in 42% cases.
As for recombinant proteins, antibodies to rOMP25
were only detected in 8% of the animals, and one cow

Table 2. Antigenicity of Brucella proteins by i-ELISA to antibodies of seropositive cows from brucellosis-affected farm.
Brucella protein antigens used in i-ELISA
*ODt/**ODc
values

CSP

rOMP25

rOMP31

rBP26

rSОD

Number of i-ELISA-positive cows
2.00 – 2.50

2

7

20

12

7

2.51 – 3.00

0

11

3

2

0

3.01 – 3.50

4

1

0

1

1

3.51 – 4.00

0

0

0

3

1

< 4.01

31

0

0

3

25

Total number (%) of seropositive animals

37 (86)

19 (44)

23 (53)

21 (49)

34 (79)

ODt/ODc mean values

8.46 ± 0.54

2.49 ± 0.08

2.31 ± 0.05

2.96 ± 0.28

8.87 ± 1.17

*ODt: OD of test serum, **ODc: mean OD of negative sera.
Table 3. Antigenicity of Brucella proteins to antibodies of cows from the focus of the brucellosis outbreak.
Brucella protein antigens used in i-ELISA
*ODt/**ODc
values

CSP

rOMP25

rOMP31

rBP26

rSОD

Number of i-ELISA-positive cows
2.00–2.50

3

20

9

12

6

2.51–3.00

2

11

8

5

2

3.01–3.50

0

5

20

5

2

3.51–4.00

3

2

10

0

0

<4.01

65

1

12

1

1

Total number (%) of seropositive animals

73 (95)

39 (51)

59 (77)

23 (30)

11 (14)

ODt/ODc mean values

6.63 ± 0.23

2.55 ± 0.08

3.5 ± 0.12

2.66 ± 0.17

3.5 ± 0.12

*ODt: OD of test serum, **ODc: mean OD of negative sera.
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Table 4. Antigenicity of Brucella proteins to sera samples of cows from a brucellosis-free farm.
Brucella protein antigens used in i-ELISA
*ODt/**ODc
values

CSP

rOMP25

rOMP31

rBP26

rSОD

Number of i-ELISA-positive cows
2.00–2.50

7

2

1

0

0

2.51–3.00

2

1

0

1

0

3.01–3.50

1

0

0

0

0

3.51–4.00

1

0

0

0

0

<4.01

0

1

0

0

0

Total number (%) of seropositive animals

11 (23)

4 (8)

1 (2)

1 (2)

0 (0)

ODt/ODc mean values

1.55 ± 0.68

1.35 ± 0.67

1.16 ± 0.36

1.07 ± 0.25

0.91 ± 0.32

*ODt: OD of test serum, **ODc: mean OD of negative sera.

each was positive for rOMP31 and rBP26, respectively.
Moreover, antibodies of these animals simultaneously
bound to rOMP25. It should be noted that antibodies
specific for rSOD were not detected in any cow from the
brucellosis-free farm.
Comparing the ODt/ODc mean values (Tables 2–4),
it can be seen that the antigenicity of Brucella proteins
was significantly higher when testing blood sera of cattle
from the brucellosis outbreak and/or endemic foci of
infection than animals kept on a brucellosis-free farm. For
example, while the ODt/ODc mean value of brucellosisfree cattle was 0.91 ± 0.32 by i-ELISA/rSOD, this indicator
reached 3.50 ± 0.12 (P ≤ 0.01) and 8.87 ± 1.17 (P ≤ 0.001)
for the herd from the brucellosis outbreak and endemic
foci, respectively. Significant differences between these
groups of animals were noted in the intensity of antiBrucella antibodies binding to other recombinant proteins:
rOMP31 and rBP26 (P ≤ 0.01), rOMP25 (P ≤ 0.05), and B.
abortus CSP (P ≤ 0.001).
4. Discussion
Maximum antibody titers in mice against rOMP25 and
rOMP31 were noted after the third injection of antigens
on day 21. Antibody production was relatively lower in
mice immunized with rSOD. In animals of this group,
the highest titers of specific antibodies were established
only by day 28 after the fourth injection of antigen. rBP26
had the highest immunogenicity among the protein
preparations tested. Thus, maximum production of
anti-rBP26 antibodies was already achieved after double
immunization of mice on day 15. Our data are consistent
with the findings of other researchers who also observed
immunological dominance of rBP26 and the possibility of
using this antigen in the serological diagnosis of human
[21] and bovine brucellosis [22].

Antiserum against Brucella CSP recognized rOMP25,
rOMP31, and rBP26, confirming the authenticity of
the recombinant proteins expressed in E. coli. These
three recombinant proteins appear to have some similar
determinants, as was evident from varying intensities of
cross-reactions. The interaction of the anti-Brucella whole
cell antibodies of hyperimmune rabbit serum with all the
recombinant proteins used in i-ELISA also confirms the
expression of the target antigens by E. coli BL21 in their
native states.
B. abortus CSP in i-ELISA was the most antigenic
among Brucella proteins used, which confirmed positive
results of 86.0% and 95% of seropositive cows kept on
brucellosis-affected and outbreak farms, respectively.
Using recombinant proteins in immunoassays
significantly reduced the number of seropositive cows as
compared with the results of RBPT and/or CFT. These
results suggest that the standard Brucella whole cell
antigen that is currently used in the serological diagnosis
of brucellosis has low specificity.
The recombinant proteins showed varying degrees
of antigenicity to antibodies of cattle kept in endemic
and/or new foci of brucellosis infection. Cows of the
latter group were better identified by i-ELISA/rOMP25
(51%) and i-ELISA/rOMP31 (77%) than by i-ELISA/
rBP26 (30%) and i-ELISA/rSOD (14%). The relatively
low antigenicity of rSOD to serum antibodies of cows
from a new brucellosis focus can be explained by the low
accessibility of superoxide dismutase in the Brucella cell.
In addition, the SOD identity of mammalian species and
Brucella may have an inhibitory effect on the humoral
immune response of both cows and experimentally
immunized mice against this enzyme [23]. Consequently,
the production of antibodies against the pathogen’s
antioxidant enzyme is delayed as compared with the host’s

491

BULASHEV et al. / Turk J Vet Anim Sci
immune response to the OMPs. As for BP26, there are
various hypotheses about its location. Some researchers
think it is a periplasmic protein [24], while others think
it is an intracellular soluble protein [25]. In either of
these cases, BP26 is also a less accessible component for
the immune system than OMPs. In this regard, antibody
production to BP26 is also delayed compared with the
immune response to proteins located on the outer cell
membrane.
rSOD-specific antibodies were not detected in the
sera of cattle from the brucellosis-free farm vaccinated
with B. abortus 19, while antibodies to rOMPs and rBP26
were detected in 2%–8% of animals. These data are not
consistent with the results of researchers who described
antiprotein antibody response only in ruminants with
active brucellosis [26]. Moreover, in a mouse model, it was
found that i-ELISA based on combined rOMPs was able
to differentiate infected mice from ones vaccinated with B.
melitensis Rev.1 [19]. Our results showed that antiprotein
antibody response could also be developed by vaccinated
animals.
B. abortus CSP, although it consists of cell wall
proteins, contains LPS impurities. Therefore, we postulate
that the lower sensitivity of i-ELISA/rOMPs compared to
i-ELISA/B. abortus CSP is due to the higher specificity of
the first variant of the immunoassay. Furthermore, our
results show that the use of a single recombinant Brucella
protein reduced the sensitivity of i-ELISA. Thus, there was

not a single protein among the rOMPs that would show
the total positive results of all proteins used.
These results allow us to conclude that i-ELISA
based on rOMP25 and/or rOMP31 is more sensitive for
detecting antibodies in cattle from a new brucellosis focus,
whereas the periplasmic proteins (rBP26 and rSOD) are
far superior to OMPs for testing animals of a brucellosisaffected farm. We believe that Brucella OMPs are useful as
antigens for screening cattle of brucellosis-free areas for
early detection of infected animals, whereas periplasmic
proteins are useful for scheduled serological examinations
of animals kept in brucellosis-affected areas. In our view,
a more appropriate approach in improving the serological
diagnosis of brucellosis is developing ELISA kits based on
a multiprotein recombinant antigen, which can be used to
test animals regardless of their location area. The efficiency
of such tests should be evaluated not only in comparison
with serological methods, but also bacteriological analysis,
which is considered the gold standard for diagnosis of
brucellosis.
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